EFFECTOR Therapeutics Income from Continuous Operations 2021-2024 | EFTR

EFFECTOR Therapeutics income from continuous operations from 2021 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

EFFECTOR Therapeutics Income from Continuous Operations 2021-2024 | EFTR

EFFECTOR Therapeutics income from continuous operations from 2021 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$142.2B
Bristol Myers Squibb (BMY)$117.1B
Gilead Sciences (GILD)$117.1B
Vertex Pharmaceuticals (VRTX)$105.1B
CSL (CSLLY)$85.9B
Regeneron Pharmaceuticals (REGN)$78.5B
GSK (GSK)$70.5B
Argenex SE (ARGX)$38B
Alnylam Pharmaceuticals (ALNY)$31.4B
BioNTech SE (BNTX)$27.4B
Biogen (BIIB)$21.7B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$17.7B
Moderna (MRNA)$15.5B
Genmab (GMAB)$13.5B
Incyte (INCY)$13.5B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.6B
Bio-Techne Corp (TECH)$11.6B
Exact Sciences (EXAS)$10.8B
Vaxcyte (PCVX)$10.7B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B